IL1B and Alzheimer disease: Low oral administration of EGCG and/or ferulic acid (30 mg/kg each) once daily inhibited oxidative stress and neuroinflammatory markers (e.g., TNF-α and IL-1β), reverted cognitive impairment, and mitigated synaptotoxicity and cerebral vascular β-amyloid deposits in AD transgenic mice after 3 months [113].